SREBF1 and metabolic dysfunction-associated steatotic liver disease: Using a high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) model, PZH could significantly (i) revert the hepatic lipid degeneration, (ii) reduce the levels of AST, ALT, gamma-GT and TG, (iii) improve hepatocyte steatosis, (iv) reduce hepatocyte necrosis and inflammatory cell infiltration, and (v) regulate the expression of key factors of lipid metabolism (Farnesoid X Receptor (FXR), Small Heterodimer Partner (SHP), Sterol-regulatory Element Binding Protein-1c (SREBP-1c)) [58].